Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
SHERMAN, STEVEN I
One or more keywords matched the following items that are connected to SHERMAN, STEVEN I
Item TypeName
Academic Article Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Concept Anilides
Academic Article Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Academic Article Cabozantinib in progressive medullary thyroid cancer.
Academic Article A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer.
Academic Article Thyroid carcinoma, version 2.2014.
Academic Article Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
Academic Article Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.
Academic Article Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
Academic Article Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
Academic Article Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
Search Criteria
  • Anilides